REGULATORY SCIENCE &
HEALTHCARE POLICY
Our experts can help you devise effective regulatory strategies to place you on the best path toward regulatory approval.
ADVICE ON
• EU/USA device regulation
• Device-drug combinations
• Validation of remote monitoring devices
STRATEGIC ADVICE FOR REGULATORY MEETINGS
• Identification of critical points
• Review of documents
• Participation in meetings
• Debriefing
SUPPORT SCIENTIFIC ADVICE PROCESSES INCLUDING RESPONSE TO REGULATORY LISTS OF QUESTIONS
SUPPORT FOR ORPHAN DRUG
REGULATORY PROCESS
• Orphan Drug Designation
• Rare Pediatric Disease Designation & Priority Review Voucher Programs
• Protocol Assistance / Scientific Advice
ASSISTANCE IN DEVELOPING REGULATORY SUBMISSION DOCUMENTS
• EMA: SME statutes, scientific advice, PRIME (priority medicines), CTA, CTD, PIP.
• FDA: scientific advice, Fast track designation, breakthrough therapy designation, priority review, accelerated approval, IND, BLA/NDA
• ANSM: Scientific Advice (GIO)